September 9, 2024 7:25am

After so much selling, the cell and gene therapy sector may be due (after 4 negative sector closings) for a bounce but it doesn't have to be all on Monday but slow upside moves will motivate “uncle algo and his electronic trading dwarfs” to “rule” in

After the stock market rally suffered its worst weekly losses in more than year

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

Never leave an investor uninformed

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

 

Monday: The pre-open Dow futures are UP +0.64% or (+258 points), the S&P futures are UP +70% or (+37 points) and the Nasdaq futures are UP +0.81% or (+150 points)

  • U.S. stock futures jumped Monday, September 9, 2024
  • European stocks were higher,
  • Asia-Pacific markets fell on Monday

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Friday: The Dow closed DOWN -410.34 points or -1.01%, the S&P closed DOWN -94.99 points or -1.73% while the Nasdaq closed DOWN -436.83 points or -2.55%

  • Friday’s advance/decline line ended with a negative at the close of 4 incliner, 29 decliners and 2 flats

Last week, the Dow slumped -2.9% the S&P 500 index tumbled -4.25% - their worst weekly losses since March 2023, while the Nasdaq plunged -5.8%, its worst week since January 2022.

Economic Data Docket: New York Fed one-year inflation expectations, August (2.97% previously); Wholesale inventories, July final (0.3% expected, 0.3% previously)

 

Friday’s RegMed Investors (RMi) Closing bell: “cell and gene therapy equities lost altitude as jobs report misses expectations, creating severe headwinds causing a dramatic loss of lift value. I continue to ask “Why no one company is immune in the sector of economic inflation-oriented releases? Welcome to my world of defining the “grey’ in our universe!” … https://www.regmedinvestors.com/articles/13605

 

Q3/24:

  • September – 4 negative closes
  • August – I neutral, 10 positive and 11 negative closes
  • July: 1 market holiday. 1 day off, 6 negative, 1 neutral and 12 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Positive Indications:

Friday, Thursday, Wednesday, Tuesday and last Monday closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Alnylam Pharmaceuticals (ALNY) closed down -$4.70 after Thursday’s -$1.66, Wednesday’s +$0.64, Tuesday’s -$8.91 and Monday’s holiday with a positive +$0.16 or +0.06% aftermarket.

 

The BOTTOM LINE: A number of stocks holding up or showing strength crumbled in the past week, while others just hang- on.

  • Investors” should” be reducing exposure however, I would pay attention to stocks experiencing roll-overs and a little bit of upbeats for following weeks and flush out some of the risk because upsides are coming.

The signs of the Nasdaq plunging -5.8%, far below its 50-day line and nearing its 200-day on Friday, some say a very negative sign for a cell and gene therapy sector rally... I say start looking at bottoms even IF I am early.

  • When there is “blood on the street,” I believe a large number of “our universe” equities will flash buy signals … especially by “uncle algo and his electronic trading dwarfs.”

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.